Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study
oleh: Gregor Verhoef, Tadeusz Robak, Huiqiang Huang, Halyna Pylypenko, Noppadol Siritanaratkul, Juliana Pereira, Johannes Drach, Jiri Mayer, Rumiko Okamoto, Lixia Pei, Brendan Rooney, Andrew Cakana, Helgi van de Velde, Franco Cavalli
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2017-05-01 |
Deskripsi
In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free survival was significantly improved with VR-CAP (24.7 versus 14.4 months with R-CHOP; P